Clinical and Cost-effectiveness of Group Schema Therapy for Complex Eating Disorders: the GST-EAT Study
NCT ID: NCT05812950
Last Updated: 2023-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
230 participants
INTERVENTIONAL
2023-07-24
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Given the limited treatment effects of existing ED treatments, and the importance of comorbid personality pathology, there is an urgent need to examine more effective treatments for EDs. Group-schematherapy (GST) overcomes the limitations of CBT-E and preliminary results for treatment-resistant EDs are promising. However, robust evidence regarding the clinical and cost-effectiveness of GST for patients that do not benefit from CBT-E is not yet available. The central aim of this project is to investigate the clinical and cost-effectiveness of GST for EDs in patients with comorbid personality pathology, who do not show a clinically significant response in the first phase of CBT-E. This is relevant and important as studies examining the effectiveness of GST for EDs are scarce. This project is a joint research initiative of three academic centers (Dutch Universities), four large nation-wide mental health organizations, and two foundations for client empowerment and participation. Eligible patients will be randomized to either GST or continuation of their CBT-E treatment after failing to show a significant treatment response in the first phase of CBT-E. Based on encouraging findings from previous studies and our own pilot data, a statistically and clinically significant better outcome in terms of ED symptoms, negative core beliefs, EMS, schema modes, and quality of life is expected in the GST group compared to the CBT-E group. GST is also expected to be more cost-effective compared to CBT-E as GST may in the long run prevent chronicity in terms of long treatment trajectories and delayed recovery. Finally, with the proviso of good results for GST, we will disseminate and implement GST in the standard of care for EDs. This project thereby has great potential to improve clinical and cost-effectiveness of treatment for chronic EDs.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Schema Therapy for eating disorders (GST)
GST starts with 5 individual sessions for introducing the ST model, placing the ED symptoms and behaviors in the context of coping modes, and organizing these in a mode map conceptualization. Thereafter there are 26 weekly group sessions of ST for EDs, supplemented with 8 optional individual ST sessions, and a psycho-education webinar for relatives. The sessions focus on recognizing and changing personal coping modes and underlying early maladaptive schemas, and developing and strengthening the healthy adult mode. GST combines interpersonal, experiential, cognitive and behavioral elements in a unified ST approach (Farrell et al., 2014). Although not at the core of GST, addressing the physiological aspects of the ED (weight care and (restrictive) eating) is necessary and therefore also incorporated in the protocol.
Note that the participants in this condition have followed phase 1 and 2 of CBT-E before starting the GST, as following these phases is required to be included in the RCT.
GST
Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
Cognitive Behavioral Therapy-Enhanced (CBT-E) (TAU)
This transdiagnostic ED treatment (current standard of care/treatment of choice) consists of 20-40 individual therapy sessions, based on the transdiagnostic CBT model of EDs. CBT-E consists of four phases. In phase one, the patient creates a personal case formulation, and the focus is on psycho-education on maintaining factors and at starting well with monitoring eating behaviours and establishing a regular eating pattern. In phase two, the first phase is evaluated and a treatment plan is made. In phase three, the main mechanisms that are thought to maintain the patient's ED (over-evaluation of shape, weight, and eating, dietary restraint or restriction, being underweight, and event- or mood-triggered changes in eating behaviour), are targeted, and a relapse plan is created. Phase four focuses on evaluating the progress so far and maintaining the changes that have been obtained (Fairburn et al., 2009).
CBT-E
Outpatient eating disorder treatment (20-40 weekly individual sessions)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GST
Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
CBT-E
Outpatient eating disorder treatment (20-40 weekly individual sessions)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\) a DSM-5 diagnosis of anorexia nervosa, bulimia nervosa, or other specified ED (atypical anorexia nervosa or bulimia nervosa with a low frequency or limited duration).
Exclusion Criteria
* 2\) being in an acute psychotic mental health state at the start of the study;
* 3\) being diagnosed with an autism spectrum disorder;
* 4\) having an IQ below 80, as determined with a validated instrument;
* 5\) showing an early response after phase 1 of CBT-E.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Utrecht University
OTHER
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
GGNet Amarum
UNKNOWN
GGZ Breburg
OTHER
Accare
OTHER
Co-eur
UNKNOWN
GGZ Friesland
OTHER
University of Groningen
OTHER
Maastricht University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeffrey Roelofs
Principal investigator J. Roelofs, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey Roelofs
Role: PRINCIPAL_INVESTIGATOR
Maastricht University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GGz Breburg
Breda, , Netherlands
Accare
Groningen, , Netherlands
GGZ Friesland
Leeuwarden, , Netherlands
GGNet Amarum
Nijmegen, , Netherlands
GGz Breburg
Tilburg, , Netherlands
Co-eur
Utrecht, , Netherlands
GGNet Amarum
Warnsveld, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Jeffrey Roelofs, Dr.
Role: CONTACT
Phone: +31433881607
Email: j . roelofs @ maastricht university . nl
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Diede van Limpt
Role: primary
Hermien Elgersma
Role: primary
Jacqueline Oostenbrink
Role: primary
suzanne Mares, dr.
Role: primary
Diede van Limpt
Role: primary
Esther Jansen
Role: primary
Suzanne Mares, dr.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Mares SHW, Roelofs J, Zinzen J, Beatse M, Elgersma HJ, Drost RMWA, Evers SMAA, Elburg AAV. Clinical effectiveness, cost-effectiveness and process evaluation of group schema therapy for eating disorders: study protocol for a multicenter randomized controlled trial. BMC Psychol. 2024 Mar 4;12(1):123. doi: 10.1186/s40359-024-01624-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
60-63600-98-1131
Identifier Type: REGISTRY
Identifier Source: secondary_id
NL80491.068.22
Identifier Type: -
Identifier Source: org_study_id